BridgeBio Pharma, Inc. Common Stock (BBIO) is a publicly traded Healthcare sector company. As of August 19, 2026, BBIO trades at $82.97 with a market cap of $15.62B and a P/E ratio of -23.10. BBIO moved +3.87% today. Year to date, BBIO is +8.48%; over the trailing twelve months it is +69.28%. Its 52-week range spans $27.23 to $93.42. Analyst consensus is strong buy with an average price target of $108.56. Rallies surfaces BBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for BBIO, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $82.97 |
| Market Cap | $15.62B |
| P/E Ratio | -23.10 |
| EPS | $-3.56 |
| Dividend Yield | 0.00% |
| 52-Week High | $93.42 |
| 52-Week Low | $27.23 |
| Volume | 2.46M |
| Avg Volume | 0 |
| Revenue (TTM) | $713.07M |
| Net Income | $-702.02M |
| Gross Margin | 94.44% |
17 analysts cover BBIO: 0 strong buy, 16 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $108.56.